155 related articles for article (PubMed ID: 9202556)
1. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Buzelin JM; Delauche-Cavallier MC; Roth S; Geffriaud-Ricouard C; Santoni JP
Br J Urol; 1997 Jun; 79(6):898-904; discussion 904-6. PubMed ID: 9202556
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Roehrborn CG
Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
Buzelin JM; Roth S; Geffriaud-Ricouard C; Delauche-Cavallier MC
Eur Urol; 1997; 31(2):190-8. PubMed ID: 9076465
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Roehrborn CG; Van Kerrebroeck P; Nordling J
BJU Int; 2003 Aug; 92(3):257-61. PubMed ID: 12887479
[TBL] [Abstract][Full Text] [Related]
6. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
Kirby RS
Eur Urol; 1998; 33 Suppl 2():19-27. PubMed ID: 9556192
[TBL] [Abstract][Full Text] [Related]
7. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
Debruyne FM; Jardin A; Colloi D; Resel L; Witjes WP; Delauche-Cavallier MC; McCarthy C; Geffriaud-Ricouard C
Eur Urol; 1998 Sep; 34(3):169-75. PubMed ID: 9732187
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
van Kerrebroec P; Jardin A; van Cangh P; Laval KU;
Eur Urol; 2002 Jan; 41(1):54-60; discussion 60-1. PubMed ID: 11999466
[TBL] [Abstract][Full Text] [Related]
9. Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
Hartung R; Matzkin H; Alcaraz A; Emberton M; Harving N; van Moorselaar J; Elhilali M; Vallancien G;
J Urol; 2006 Feb; 175(2):624-8; discussion 628. PubMed ID: 16407011
[TBL] [Abstract][Full Text] [Related]
10. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.
McNeill SA; Daruwala PD; Mitchell ID; Shearer MG; Hargreave TB
BJU Int; 1999 Oct; 84(6):622-7. PubMed ID: 10510105
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
Sánchez-Chapado M; Guil M; Alfaro V; Badiella L; Fernández-Hernando N
Eur Urol; 2000 Apr; 37(4):421-7. PubMed ID: 10765072
[TBL] [Abstract][Full Text] [Related]
13. Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction.
Buzelin JM; Delauche Cavallier MC; Martin D; Angel I
Br J Urol; 1998 Apr; 81(4):655-6. PubMed ID: 9598661
[No Abstract] [Full Text] [Related]
14. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
15. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Elhilali M; Emberton M; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Alcaraz A; Vallancien G;
BJU Int; 2006 Mar; 97(3):513-9. PubMed ID: 16469018
[TBL] [Abstract][Full Text] [Related]
17. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
[TBL] [Abstract][Full Text] [Related]
18. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
19. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
Marks LS; Roehrborn CG; Gittelman M; Kim D; Forrest J; Jacobs S
Urology; 2003 Nov; 62(5):888-93. PubMed ID: 14624914
[TBL] [Abstract][Full Text] [Related]
20. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Roehrborn CG
Urology; 2001 Dec; 58(6 Suppl 1):55-63; discussion 63-4. PubMed ID: 11750253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
